Dr. Aaron Gaudiel Boonjindasup, MD

Dr. Boonjindasup practices at ENT Associates Medical Group in Oceanside, California.

Dr. Boonjindasup's NPI, 1407146749, was assigned on April 7, 2011. Dr. Boonjindasup graduated from Tulane School of Medicine in 2011. Dr. Boonjindasup holds California license 143323.

Dr. Boonjindasup's primary practice is ENT Associates Medical Group, at 3907 Waring Rd, Oceanside, CA 92056 in San Diego County. The practice phone is (760) 724-8749.

Dr. Boonjindasup's primary practice is ENT Associates Medical Group in Oceanside, California. Dr. Boonjindasup is also affiliated with Sharp Tri-City Medical Center. The medical group on file is Urology San Diego. Dmand AI also links Dr. Boonjindasup to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Boonjindasup practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Boonjindasup's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Boonjindasup is board certified in urology by the American Board of Urology. Dr. Boonjindasup is licensed in California.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease, pelvic prolapse and prostate cancer among the conditions Dr. Boonjindasup treats.

CMS data shows 1,070 Medicare services from Dr. Boonjindasup across 15 procedure codes in 2024, for 318 Medicare patients. Medicare paid $96,139 for them.

CMS counts 318 Medicare patients who saw Dr. Boonjindasup in 2024. The largest group is 75 to 84, with 139 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.45, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Boonjindasup's median patient age at 70, with 30% women.

In 2024, Dr. Boonjindasup wrote 1,299 Medicare Part D claims for 347 patients. 87% of them were for generic drugs. CMS names the drug for 1,181 of them, across 27 drugs with 11 or more claims each, at $439,708 in total drug cost. In 2023, CMS named 1,002 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Boonjindasup for performance year 2024, reported as part of a group. Dr. Boonjindasup accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Boonjindasup as offering telehealth. CMS counts 15 procedures of prostate resection by Dr. Boonjindasup, more than 72% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 9 papers to Dr. Boonjindasup, published from 2011 to 2016. 2015 was the busiest year, with 4. The most frequent topics are Penile Prosthesis and Reoperation. Dr. Boonjindasup has published most often in Int J Impot Res. Dr. Boonjindasup's most frequent co-authors are Michael M. Maddox, MD, Landon Westlund Trost, MD and Erik Peter Castle, MD.

CMS Open Payments shows 599 general payments to Dr. Boonjindasup from 69 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 78% of the total. Boston Scientific Corporation paid the most, $2,051.

Dr. Boonjindasup graduated from Tulane School of Medicine in 2011.

Dr. Boonjindasup is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.